Comparison 1. Bile acids for acute hepatitis B.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Risk of having positive serum HBsAg at the end of treatment	1	61	Risk Ratio (M‐H, Fixed, 95% CI)	0.40 [0.17, 0.92]
1.1 UDCA versus placebo	1	61	Risk Ratio (M‐H, Fixed, 95% CI)	0.40 [0.17, 0.92]
2 Risk of having positive HBsAg at the end of follow‐up	1	61	Risk Ratio (M‐H, Fixed, 95% CI)	0.23 [0.05, 1.00]
2.1 UDCA versus placebo	1	61	Risk Ratio (M‐H, Fixed, 95% CI)	0.23 [0.05, 1.00]
3 Serum DNA (pg/ml) level at the end of treatment	1	59	Mean Difference (IV, Fixed, 95% CI)	‐574.05 [‐1148.71, 0.61]
3.1 UDCA versus placebo	1	59	Mean Difference (IV, Fixed, 95% CI)	‐574.05 [‐1148.71, 0.61]
4 Serum DNA (pg/ml) level at the end of follow‐up	1	59	Mean Difference (IV, Fixed, 95% CI)	‐954.73 [‐1813.71, ‐95.75]
4.1 UDCA versus placebo	1	59	Mean Difference (IV, Fixed, 95% CI)	‐954.73 [‐1813.71, ‐95.75]
5 Risk of abnormal serum ALT at the end of treatment	1	61	Risk Ratio (M‐H, Fixed, 95% CI)	0.35 [0.12, 1.02]
5.1 UDCA versus placebo	1	61	Risk Ratio (M‐H, Fixed, 95% CI)	0.35 [0.12, 1.02]
6 Risk of abnormal serum ALT at the end of follow‐up	1	61	Risk Ratio (M‐H, Fixed, 95% CI)	0.26 [0.06, 1.21]
6.1 UDCA versus placebo	1	61	Risk Ratio (M‐H, Fixed, 95% CI)	0.26 [0.06, 1.21]
7 Risk of abnormal serum GGT at the end of treatment	1	61	Risk Ratio (M‐H, Fixed, 95% CI)	0.32 [0.11, 0.90]
7.1 UDCA versus placebo	1	61	Risk Ratio (M‐H, Fixed, 95% CI)	0.32 [0.11, 0.90]
8 Risk of abnormal serum GGT at the end of follow‐up	1	61	Risk Ratio (M‐H, Fixed, 95% CI)	0.26 [0.06, 1.21]
8.1 UDCA versus placebo	1	61	Risk Ratio (M‐H, Fixed, 95% CI)	0.26 [0.06, 1.21]